{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:30:50Z","timestamp":1789014650263,"version":"build-2803163510"},"reference-count":34,"publisher":"American Society of Hematology","issue":"5","license":[{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3,12]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Patients with high-grade B-cell lymphoma with MYC and BCL2 rearrangements (HGBL-MYC\/BCL2) respond poorly to immunochemotherapy compared with patients with diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) without a MYC rearrangement. This suggests a negative impact of lymphoma-intrinsic MYC on the immune system. To investigate this, we compared circulating T cells and natural killer (NK) cells of patients with HGBL-MYC\/BCL2 (n\u00a0= 66), patients with DLBCL NOS (n\u00a0= 53), and age-matched healthy donors (HDs; n\u00a0= 16) by flow cytometry and performed proliferation, cytokine production, and cytotoxicity assays. Compared with HDs, both lymphoma subtypes displayed similar frequencies of CD8+ T cells but decreased CD4+ T cells. Regulatory T-cell (Treg) frequencies were reduced only in patients with DLBCL NOS. Activated (HLA-DR+\/CD38+) T cells, PD-1+CD4+ T cells, and PD-1+Tregs were increased in both lymphoma subtypes, but PD-1+CD8+ T\u00a0cells were increased only in HGBL-MYC\/BCL2. Patients with DLBCL NOS, but not patients with HGBL-MYC\/BCL2, exhibited higher frequencies of senescent T cells than HDs. Functional assays showed no overt differences between both lymphoma groups and HDs. Deeper analyses revealed that PD-1+ T cells of patients with HGBL-MYC\/BCL2 were exhausted with impaired cytokine production and degranulation. Patients with DLBCL NOS, but not patients with HGBL-MYC\/BCL2, exhibited higher frequencies of NK cells expressing inhibiting receptor NKG2A. Both lymphoma subtypes exhibited lower TIM-3+\u2013 and DNAM-1+\u2013expressing NK cells. Although NK cells of patients with HGBL-MYC\/BCL2 showed less degranulation, they were not defective in cytotoxicity. In conclusion, our results demonstrate an increased exhaustion in circulating T cells of patients with HGBL-MYC\/BCL2. Nonetheless, the overall intact peripheral T-cell and NK-cell functions in these patients emphasize the importance of investigating potential immune evasion in the microenvironment of MYC-rearranged lymphomas.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011687","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T03:29:01Z","timestamp":1704770941000},"page":"1094-1104","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["Distinct peripheral T-cell and NK-cell profiles in HGBL-<i>MYC\/BCL2<\/i> vs patients with DLBCL NOS"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5397-1762","authenticated-orcid":false,"given":"A. Vera","family":"de Jonge","sequence":"first","affiliation":[{"name":"1Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands"},{"name":"2Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolien","family":"Duetz","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands"},{"name":"2Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4074-9257","authenticated-orcid":false,"given":"Wassilis S. C.","family":"Bruins","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands"},{"name":"2Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte L. B. M.","family":"Korst","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands"},{"name":"2Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3317-437X","authenticated-orcid":false,"given":"Rosa","family":"Rentenaar","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands"},{"name":"2Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meliha","family":"Cosovic","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands"},{"name":"2Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merve","family":"Eken","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands"},{"name":"2Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inoka","family":"Twickler","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands"},{"name":"2Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2740-2873","authenticated-orcid":false,"given":"Marcel","family":"Nijland","sequence":"additional","affiliation":[{"name":"4Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein W. M.","family":"van der Poel","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Department of Internal Medicine, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"de Heer","sequence":"additional","affiliation":[{"name":"3Department of Internal Medicine, Flevoziekenhuis, Almere, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara P. W.","family":"Klerk","sequence":"additional","affiliation":[{"name":"6Department of Internal Medicine, Dijklanderziekenhuis, Hoorn, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie","family":"Strobbe","sequence":"additional","affiliation":[{"name":"7Department of Internal Medicine, Gelreziekenhuizen, Zutphen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6742-9261","authenticated-orcid":false,"given":"Margriet","family":"Oosterveld","sequence":"additional","affiliation":[{"name":"8Department of Internal Medicine, CWZ, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinske","family":"Boersma","sequence":"additional","affiliation":[{"name":"9Department of Internal Medicine, Amphia Ziekenhuis, Breda, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry R.","family":"Koene","sequence":"additional","affiliation":[{"name":"10Department of Hematology, St Antonius Ziekenhuis, Nieuwegein, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaretha G. M.","family":"Roemer","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands"},{"name":"2Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7469-7427","authenticated-orcid":false,"given":"Erik","family":"van Werkhoven","sequence":"additional","affiliation":[{"name":"11HOVON Foundation, Rotterdam, The Netherlands"},{"name":"12Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine E. D.","family":"Chamuleau","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands"},{"name":"2Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5557-7187","authenticated-orcid":false,"given":"Tuna","family":"Mutis","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands"},{"name":"2Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,2,28]]},"reference":[{"issue":"7","key":"2024031115455829100_bib1","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"17","key":"2024031115455829100_bib2","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1182\/blood-2009-05-220095","article-title":"MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy","volume":"114","author":"Savage","year":"2009","journal-title":"Blood"},{"issue":"20","key":"2024031115455829100_bib3","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2009.26.3947","article-title":"Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab","volume":"28","author":"Barrans","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2024031115455829100_bib4","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.3324\/haematol.2018.190157","article-title":"Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements is not associated with MYC\/IG gene rearrangements","volume":"103","author":"McPhail","year":"2018","journal-title":"Haematologica"},{"issue":"10306","key":"2024031115455829100_bib5","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"2024031115455829100_bib6","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a human CD20xCD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol"},{"issue":"24","key":"2024031115455829100_bib7","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"2024031115455829100_bib8","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024031115455829100_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"2024031115455829100_bib10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"10254","key":"2024031115455829100_bib11","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"2024031115455829100_bib12","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.3389\/fonc.2020.01290","article-title":"Mechanisms of cancer resistance to immunotherapy","volume":"10","author":"Bai","year":"2020","journal-title":"Front Oncol"},{"issue":"5","key":"2024031115455829100_bib13","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"issue":"1","key":"2024031115455829100_bib14","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1038\/s41467-020-16447-7","article-title":"MYC functions as a switch for natural killer cell-mediated immune surveillance of lymphoid malignancies","volume":"11","author":"Swaminathan","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"2024031115455829100_bib15","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s12885-019-5529-0","article-title":"Altered profile of immune regulatory cells in the peripheral blood of lymphoma patients","volume":"19","author":"Amini","year":"2019","journal-title":"BMC Cancer"},{"issue":"1","key":"2024031115455829100_bib16","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12885-023-10657-0","article-title":"Peripheral immune cell profiling of double-hit lymphoma by mass cytometry","volume":"23","author":"Lei","year":"2023","journal-title":"BMC Cancer"},{"issue":"20","key":"2024031115455829100_bib17","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2024031115455829100_bib18","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/cyto.a.24501","article-title":"PeacoQC: peak-based selection of high quality cytometry data","volume":"101","author":"Emmaneel","year":"2022","journal-title":"Cytometry A"},{"issue":"2","key":"2024031115455829100_bib19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/cyto.a.21010","article-title":"Interpretation of cellular proliferation data: avoid the panglossian","volume":"79","author":"Roederer","year":"2011","journal-title":"Cytometry A"},{"issue":"12","key":"2024031115455829100_bib20","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.it.2016.09.002","article-title":"Senescence of T lymphocytes: implications for enhancing human immunity","volume":"37","author":"Akbar","year":"2016","journal-title":"Trends Immunol"},{"issue":"6","key":"2024031115455829100_bib21","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/s41590-020-0643-3","article-title":"Sestrins induce natural killer function in senescent-like CD8(+) T cells","volume":"21","author":"Pereira","year":"2020","journal-title":"Nat Immunol"},{"issue":"6769","key":"2024031115455829100_bib25","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"2","key":"2024031115455829100_bib26","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","article-title":"Genetic and functional drivers of diffuse large B cell lymphoma","volume":"171","author":"Reddy","year":"2017","journal-title":"Cell"},{"issue":"15","key":"2024031115455829100_bib27","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2024031115455829100_bib28","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"issue":"4","key":"2024031115455829100_bib29","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A\u00a0probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"issue":"1","key":"2024031115455829100_bib30","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/bjh.18816","article-title":"Early lymphocyte collection for anti-CD19 CART production improves T-cell fitness in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"202","author":"Dubnikov Sharon","year":"2023","journal-title":"Br J Haematol"},{"issue":"6","key":"2024031115455829100_bib31","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1159\/000449251","article-title":"Influence of R-CHOP therapy on immune system restoration in patients with B-cell lymphoma","volume":"91","author":"Ito","year":"2016","journal-title":"Oncology"},{"issue":"19","key":"2024031115455829100_bib32","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1182\/bloodadvances.2020001797","article-title":"Lingering effects of chemotherapy on mature T cells impair proliferation","volume":"4","author":"Das","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"2024031115455829100_bib33","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00018-011-0860-x","article-title":"Tumor microenvironment: becoming sick of Myc","volume":"69","author":"Whitfield","year":"2012","journal-title":"Cell Mol Life Sci"},{"issue":"10","key":"2024031115455829100_bib34","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.3390\/cancers12103052","article-title":"Impact of MYC on anti-tumor immune responses in aggressive B cell non-Hodgkin lymphomas: consequences for cancer immunotherapy","volume":"12","author":"de Jonge","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2024031115455829100_bib35","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41420-023-01403-3","article-title":"The effects of MYC on tumor immunity and immunotherapy","volume":"9","author":"Li","year":"2023","journal-title":"Cell Death Discov"},{"issue":"3","key":"2024031115455829100_bib36","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1182\/bloodadvances.2021005954","article-title":"Pharmacodynamics and molecular correlates of response to glofitamab in relapsed\/refractory non-Hodgkin lymphoma","volume":"6","author":"Br\u00f6ske","year":"2022","journal-title":"Blood Adv"},{"issue":"5","key":"2024031115455829100_bib37","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood.2021011994","article-title":"Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities","volume":"141","author":"Falchi","year":"2023","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/5\/1094\/2217710\/blooda_adv-2023-011687-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/5\/1094\/2217710\/blooda_adv-2023-011687-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T15:46:28Z","timestamp":1710171988000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/5\/1094\/506981\/Distinct-peripheral-T-cell-and-NK-cell-profiles-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,28]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,3,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011687","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,28]]}}}